Our Story
VisionTransforming Health in Singapore through Precision MedicineMissionCoordinate a whole of government effort to implement Singapore’s National Precision Medicine programme, to drive at the national level: data-driven healthcare, improved patient outcomes and economic value capture. |
Precision Health Research, Singapore (PRECISE) is the central entity set up to coordinate a whole of government effort to implement Phase II of Singapore’s 10-year National Precision Medicine (NPM) strategy. NPM Phase II aims to transform healthcare in Singapore and improve patient outcomes through new insights into the Asian genome and data-driven healthcare solutions. NPM Phase II will also enhance the breadth and depth of the Precision Medicine-related industry by attracting and anchoring overseas companies in Singapore while yielding new opportunities for home-grown companies. |
|
Precision Medicine is one of the key goals of Singapore’s Research, Innovation and Enterprise (RIE) 2025 vision for Health and Biomedical Sciences. Precision medicine offers an effective means of translating research into more efficient healthcare delivery systems and better health for Singaporeans. Singapore’s National Precision Medicine Strategy is a 10-year research roadmap to accelerate biomedical research, improve health outcomes and enhance opportunities for economic value across sectors. |
|
Our Story
Making precision medicine in Singapore possible requires long-term commitments from both the government and private industries. This strategy will be implemented as three phases.
Phase 1 of Singapore’s National Precision Medicine (NPM) programme set the stage by establishing a Singaporean reference database containing 10,000 genomes, and partnering with industry as co-investors in the NPM programme.
Phase 2 was launched in 2020 and aims to generate the genomes of 100,000 healthy Singaporeans and 50,000 people with specific diseases. Phase 2 will pilot clinical implementation of precision medicine approaches and establish data infrastructure for the linkage of genomic data with electronic health records and other data types. Precision Health Research, Singapore (PRECISE) is the central entity incorporated to coordinate Phase 2.
Phase 3 will implement precision medicine in Singapore on a large scale and is expected to span from 2025 to 2030. Besides genomic sequencing of approximately 10% of Singapore’s population, the genomic data will be linked with clinical and lifestyle data to create large Singaporean databases. Ultimately, doctors and scientists can use these valuable resources to reach a deeper understanding of how diseases develop, and discover better ways to prevent and treat them.
Video: Singapore’s National Precision Medicine Strategy
